Novel Path to Immune and Inflammatory Therapies
Lifordi is developing new therapies for autoimmune and inflammatory
disorders using a novel, targeted ADC based delivery platform
Lifordi’s ADC-based delivery platform targets VISTA, a cell surface protein mainly expressed on immune cells, including myeloid and lymphoid cells. This innovative approach could offer a new way to target autoimmune and inflammatory conditions across a number of disciplines, including rheumatology, gastroenterology, pulmonology, and dermatology.
The unique biologic properties of VISTA, including its rapid internalization and intracellular accumulation, make it an ideal ADC approach.
Payload-specific Delivery to VISTA-expressing Cells
Lifordi’s ADC-based platform is also being applied to target both innate and adaptive immune cells with diverse payloads ranging from small molecules to nucleic acids including antisense oligonucleotides (ASOs) and siRNAs. This innovative approach has been validated in multiple preclinical models and in early clinical data in healthy participants with LFD-200, Lifordi’s first ADC program currently in Phase 1 studies.
T Cells
CD3/Anti-payload/DAPI
Macrophages
F4/80 /Anti-payload/DAPI
Dendritic Cells
CD11
/Anti-payload/DAPI
Neutrophils
MPO
/Anti-payload/DAPI
High Endothelial Venules
MECA-79
/Anti-payload/DAPI
Targeted delivery of nucleic acids to immune cells offer genome-wide opportunities to address unmet need. Using an ADC approach addresses poor drug properties typically associated with nucleic acid therapeutics including short serum half-life, limited exposure, and systemic toxicity as well as primary targeting liver and muscle. The Lifordi team has shown delivery of a number of nucleic acid payloads specifically to VISTA expressing cells resulting in long immune tissue exposure and functional impact in vitro and in vivo supporting pipeline expansion and partnership opportunities. Lifordi’s lead ASO ADC candidate has demonstrated efficacy in multiple Th2-driven disease models and is currently in lead optimization stage.
Many opportunities exist to develop ADCs for diverse payloads to control immune cell functions. If you are interested in discussing partnership opportunities, please reach out to info@lifordi.com.